|
Marín F, Roldán V, Lip GY. Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable? Expert Opin Pharmacother. 2012 Jun;13(8):1087-90. doi: 10.1517/14656566.2012.688954. Epub 2012 May 9. PubMed PMID: 22568622.
AÑO: 2012; IF: 2.86
|
22568622
|
Gallego P, Roldán V, Torregrosa JM, Gálvez J, Valdés M, Vicente V, Marín F, Lip GY. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2012 Apr;5(2):312-8. doi: 10.1161/CIRCEP.111.967000. Epub 2012 Feb 7. PubMed PMID: 22319005.
AÑO: 2012; IF: 1.241
|
|
Roldán V, Marín F, Manzano-Fernández S, Gallego P, Vílchez JA, Valdés M, Vicente V, Lip GY. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2013 Dec 10;62(23):2199-204. doi: 10.1016/j.jacc.2013.08.1623. PubMed PMID: 24055744.
AÑO: 2013; IF: 15.343
|
|
Vílchez JA, Roldán V, Manzano-Fernández S, Fernández H, Avilés-Plaza F, Martínez-Hernández P, Vicente V, Valdés M, Marín F, Lip GY. ?-Trace protein and prognosis in patients with atrial fibrillation receiving anticoagulation treatment. Chest. 2013 Nov;144(5):1564-70. doi: 10.1378/chest.13-0922. PubMed PMID: 23975142.
AÑO: 2013; IF: 7.132
|
|
Gallego P, Roldan V, Marín F, Romera M, Valdés M, Vicente V, Lip GY. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost. 2013 Dec;110(6):1189-98. doi: 10.1160/TH13-07-0556. PubMed PMID: 24096615.
AÑO: 2013; IF: 5.76
|